No association of apolipoprotein E ε4 genotype with faster progression or less recovery of relapses in a Spanish cohort of multiple sclerosis

Abstract

Background Recent data have suggested a faster deterioration of multiple sclerosis (MS) patients who harbour the o4 allele of the apolipoprotein E (APOE) gene. We investigate the relationship of APOE genotypes with disease severity and clinical recovery of relapses in a MS population of the north of Spain.

Methods One hundred and thirty-three patients with clinically defined MS were studied. Disease course (relapsing versus progressive), age of onset, duration of the disease and disability measured by the Expanded Disability Status Scale (EDSS) were recorded. Worsening was measured by the Progression Index (PI) and by EDSS 4 and 6 latencies. In 79 patients with relapsing-remitting (RR) MS the degree of clinical recovery of relapses (total versus partial) was assessed.

Results The frequency of the APOE o4 allele in our patients was similar to that found in other southern European populations. APOE o4 patients did not have a faster progression as assessed by PI and EDSS 4 and 6 latencies. Among 79 patients with RRMS there were no significant differences in the degree of recovery of relapses.

Conclusions In this MS population, APOE o4 polymorphism is not associated with a more severe clinical course and does not appear to influence recovery of exacerbations.

Keywords

apolipoprotein E MS progression MS relapse recovery multiple sclerosis

Get full access to this article

View all access options for this article.

References

Weinshenker BG , Kantarci OH. Seeking genes for MS: big risk for big gains . Neurology 2000; 54: 542-544 .

Mahley R. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology . Science 1998; 240: 622-630 .

Beffert U , Danik M , Kryzwkowski P , Ramassamy C , Berrada F , Poirier J et al. The neurobiology of apolipoproteins and their receptors in the CNS and Alzheimer’s disease . Brain Res Rev 1998; 27: 119-142 .

Poirier J. Apolipoprotein E in the brain and its role in Alzheimer’s disease . J Psychiatr Neurosci 1996; 21: 128-134 .

Saunders AM , Strittmatter WJ , Schmechel D , George-Hyslop PH , Pericak-Vance MA , Joo SH et al. Association of apolipoprotein E allele E4 with late onset familial and sporadic Alzheimer disease . Neurology 1993; 43: 1467-1472 .

Weatherby SJ , Mann CL , Davies MB , Carthy D , Fryer A , Boggild MD et al. Polymorphisms of apolipo-protein E; outcome and susceptibility in multiple sclerosis . Mult Scler 2000; 6: 32-36 .

Masterman T , Zhang Z , Hellgren D , Salter H , Anvret M , Lilius L et al. APOE Genotypes and disease severity in multiple sclerosis . Mult Scler 2002; 8: 98-103 .

Ferri C , Sciacca FL , Veglia F , Martinelli F , Comi G , Canal N et al. APOE o2-4 and -491 polymorphisms are not associated with MS . Neurology 1999; 53: 888-889 .

Savettieri G , Andreoli U , Bonavita S , Citadella R , Caltagirone C , Fazio MC et al. Apolipoprotein E genotype does not influence the progression of multiple sclerosis . J Neurol 2003; 250: 1094-1098 .

10.

Guerrero AL , Bueno V , Hernandez MT , Martín-Serradilla JI , Carrasco E , Cuadrado I. Apolipoprotein E polymorphism as predictor of progression of multiple sclerosis . Neurologia 2003; 18: 146-148 .

11.

Santos M , do Carmo Costa M , Edite Rio M , Jose Sa M , Monteiro M , Valenca A et al. Genotypes at the APOE and SCA2 loci do not predict the course of multiple sclerosis in patients of Portuguese origin . Mult Scler 2004; 10: 153-157 .

12.

Zwemmer JN , van Veen T , van Winsen L , van Kamp GJ , Barkhof F , Polman CH et al. No major association of Apo E genotype with disease characteristics and MRI findings in multiple sclerosis . Mult Scler 2004; 10: 272-277 .

13.

Evangelou N , Jackson M , Besson D , Palace J. Association of the APOE E4 allele with disease activity in multiple sclerosis . J Neurol Neurosurg Psychiatry 1999; 67: 203-205 .

14.

Hogh P , Oturai A , Schreiber K , Blinkenberg M , Jorgensen O , Ryder L et al. Apolipoprotein E and multiple sclerosis: impact of the epsilon-4 allele on susceptibility, clinical type and progression rate . Mult Scler 2000; 6: 226-230 .

15.

Chapman J , Vinokurov S , Achiron A , Karussis DM , Mitosek-Szewczyk K , Birnbaum M et al. APOE genotype is a major predictor of long-term progression of disability in MS . Neurology 2001; 56: 312-316 .

16.

Fazekas F , Strasser-Fuchs S , Kolleger H , Berger T , Kristoferictsch W , Schmidt H et al. Apolipoprotein E o4 is associated with rapid progression of multiple sclerosis . Neurology 2001; 57: 853-857 .

17.

Frederiksen JL , Pinholt M , Christiansen M , Andersen P , Glostrup KAS. Association between apolipoprotein E, multiple sclerosis and acute monosymptomatic opticus neuritis . Mult Scler 2004; 11: P443-P443 (Abstract).

18.

Poser CM , Paty DW , Scheinberg L , McDonald WI. New diagnostic criteria for multiple sclerosis: guidelines for research protocols . Ann Neurol 1983; 13: 227-231 .

19.

Sipe JC , Knobler RL , Braheny SL , Rice GP , Panitch HS , Oldstone MB. A neurologic rating scale (NRS) for use in multiple sclerosis . Neurology 1984; 34: 1368-1372 .

20.

Runmarker B , Anderson C , Oden A , Andersen O. Prediction of outcome in multiple sclerosis based on multivariate models . J Neurol 1994; 241: 597-604 .

21.

Muros M , Rodríguez-Ferrer C. Apolipoprotein E polymorphism influence on lipids, apolipoproteins and Lp(a) in a Spanish population underexpressing apoE4 . Atherosclerosis 1996; 121: 13-21 .

22.

Gomez-Coronado D , Alvarez JJ , Entrala A , Olmos JM , Herrera E , Lasuncion MA et al. Apolipoprotein E polymorphism in men and women from a Spanish population: allele frequencies and influence on plasma lipids and apolipoproteins . Atherosclerosis 1999; 147: 167-176 .

23.

Lucotte G , Loirat F , Hazout S. Pattern of gradient of apolipoprotein E allele ε4 frequencies in western Europe . Hum Biol 1997; 69: 253-262 .

24.

Vincent S , Planells R , Defoort C , Bernard MC , Gerber M , Prudhomme J et al. Genetic polymorphism and lipoprotein responses to diets . Proc Nutr Soc 2002; 61: 427-434 .

25.

Ribalta J , Vallve JC , Girona J , Masana L. Apolipo-protein and apolipoprotein receptor genes, blood lipids and disease . Curr Opin Clin Nutr Metab Care 2003; 6: 177-187 .

26.

Weggemans RM , Zock PL , Ordovas JM , Pedro-Botet J , Katan MB. Apoprotein E genotype and the response of serum cholesterol to dietary fat, cholesterol and cafestol . Atherosclerosis 2001; 154: 547-555 .

27.

Couture P , Archer WR , Lamarche B , Landry N , Deriaz O , Corneau L et al. Influences of apolipoprotein E polymorphism on the response plasma lipids to the ad libitum consumption of a high-carbohydrate diet compared with a high-monounsaturate fatty acid diet . Metabolism 2003; 52: 1454-1459 .

28.

Burgos JS , Ramirez C , Sastre I , Bullido MJ , Valdivielso F. ApoE4 is more efficient than E3 in brain access by herpes simples virus type I . Neuroreport 2003; 14: 1825-1827 .

29.

Becker KG. APOE genotype is a major predictor of long-term progression of disability in MS . Neurology 2001; 57: 2148-2149 .

30.

Sadovnick AD , Dyment D , Ebers C. Genetic epidemiology of multiple sclerosis . Epidemiol Rev 1997; 19: 99-106 .

31.

Kantarci OH , Hebrink DD , Achenbach SJ , Pittock SJ , Altintas A , Schaefer-Klein JL et al. Association of APOE polymorphisms with disease severity in MS is limited to women . Neurology 2004; 62: 811-814 .

32.

De Stefano N , Bartolozzi ML , Nacmias B , Zipoli V , Mortilla M , Guidi L et al. Influence of apolipoprotein Eo4 genotype on brain tissue integrity in relapsing-remitting multiple sclerosis . Arch Neurol 2004; 61: 536-540 .

33.

Enzinger C , Ropele S , Smith S , Strasser-Fuchs S , Poltrum B , Schmidt H et al. Accelerated evolution of brain atrophy and “black holes” in MS patients with APOE-o4 . Ann Neurol 2004; 55: 563-569 .